Stockbroker · United States
Lucid Capital Markets
- Deals
- 10
- M&A
- 6
- Equity raisings
- 4
- Latest
- Jul 2026
Deals
Deals dated after 30 September 2026 are still being collected.
Columns
10 of 10 deals
| Advisers | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 2026 | Synlogic | – | – | Merger | Financial adviser to Synlogic (target) | Announced | – | Biotech+1 | Mintz (sell-side)Fenwick & West (buy-side) | Caldera Therapeutics and Synlogic merger |
| Jun 2026 | SharonAI Holdings | – | – | Placement | Placement agent to the lead managers | Completed | 1,600.0 | AI Infrastructure+2 | Goldman Sachs (lead manager)Macquarie Capital (issuer)Sheppard, Mullin, Richter & Hampton (issuer) | SharonAI Holdings placement |
| Jun 2026 | Serapha Bio | – | Boundless Bio | Merger | Financial adviser to Boundless Bio (acquirer) | Pending | – | Biotech+1 | Latham & Watkins (buy-side)Wedbush Securities (sell-side)Gibson Dunn (sell-side)Goodwin (sell-side) | Boundless Bio and Serapha Bio merger |
| Jun 2026 | Azora Therapeutics | – | Adial Pharmaceuticals | Asset sale | Financial adviser to Azora (target) | Completed | – | Biotech+2 | Oppenheimer & Co. (buy-side)Blank Rome (buy-side)Honigman (sell-side) | Adial Pharmaceuticals acquisition of Azora Therapeutics |
| Jun 2026 | Adial Pharmaceuticals | – | – | Placement | Placement agent to the lead managers | Pending | 32.0 | Biotech+1 | TD Securities (issuer) | Adial Pharmaceuticals placement |
| May 2026 | Mentari Therapeutics | – | InMed Pharmaceuticals | Acquisition | Financial adviser to InMed Pharmaceuticals (acquirer) | Announced | – | Biotech+1 | Norton Rose Fulbright (buy-side)Wedbush Securities (sell-side)Gibson Dunn (sell-side) | InMed Pharmaceuticals acquisition of Mentari Therapeutics |
| May 2026 | Exyn Technologies | – | – | IPO | Underwriter | Announced | 19.4 | Robotics+2 | DLA Piper (issuer)Loeb & Loeb (lead manager) | Exyn Technologies IPO |
| Apr 2026 | Obsidian Therapeutics | – | Galera Therapeutics | Merger | Financial adviser to Galera Therapeutics (acquirer); Fairness opinion to Galera’s Board of Directors (acquirer) | Completed | 413.5 | Biotech+2 | Sidley Austin (buy-side)Goodwin (sell-side)Leerink Partners (sell-side) | Galera Therapeutics and Obsidian Therapeutics merger |
| Mar 2026 | Swarmer | – | – | IPO | Bookrunner | Announced | 15.0 | Defence & Aerospace+1 | Mintz (issuer)Ellenoff Grossman & Schole (lead manager) | Swarmer IPO |
| Feb 2026 | Faeth Therapeutics | – | Sensei Biotherapeutics | Acquisition | Financial adviser to Sensei Biotherapeutics (acquirer) | Completed | – | Biotech+2 | Sidley Austin (buy-side)Cooley (sell-side) | Sensei Biotherapeutics acquisition of Faeth Therapeutics |
Activity
By announcement date; raisings and IPOs by their own date.
Sector of the business bought or funded.
Disclosed value in US dollars.
Most often across the table
- Goodwin
2 dealsCompare - Wedbush Securities2 dealsCompare
- Gibson Dunn
2 dealsCompare - Sidley Austin
1 dealCompare - Leerink Partners1 dealCompare
- Fenwick & West1 dealCompare
- Cooley1 dealCompare
- Oppenheimer & Co.1 dealCompare
Firms advising the other side of the same deals.